TLQP-21, a neuroendocrine VGF-derived peptide, prevents cerebellar granule cells death induced by serum and potassium deprivation.
Different VGF peptides derived from Vgf, originally identified as a nerve growth factor responsive gene, have been detected in neurons within the central and peripheral nervous system and in various endocrine cells. In the current study, we have evaluated the ability of TLQP-21, a VGF-derived peptide, to protect, in a dose- and time-dependent manner, primary cultures of rat cerebellar granule cells (CGCs) from serum and potassium deprivation-induced cell death. We demonstrated that TLQP-21 increased survival of CGCs by decreasing the degree of apoptosis as assessed by cell viability and DNA fragmentation. Moreover, TLQP-21 significantly activated extracellular signal-regulated kinase 1/2, serine/threonine protein kinase, and c-jun N-terminal kinase phosphorylation, while decreased the extent of protein kinase C phosphorylation, as demonstrated by western blot analysis. In addition, TLQP-21 induced significant increase in intracellular calcium (as measured by fura-2AM) in about 60% of the recorded neurons. Taken together, the present results demonstrate that TLQP-21 promotes the survival of CGCs via pathways involving, within few minutes, modulation of kinases associated with CGCs survival, and by increasing intracellular calcium which can contribute to the neuroprotective effect of the peptide.
Severini
Cinzia
C
Institute of Neurobiology and Molecular Medicine, CNR, Rome, Italy. c.severinii@inmm.cnr.it
Ciotti
Maria Teresa
MT
Biondini
Laura
L
Quaresima
Stefania
S
Rinaldi
Anna Maria
AM
Levi
Andrea
A
Frank
Claudio
C
Possenti
Roberta
R
D000704:Analysis of Variance; D000818:Animals; D002070:Butadienes / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D002352:Carrier Proteins / Q000378:metabolism*; D002531:Cerebellum / Q000166:cytology*; D053938:DNA Fragmentation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004622:Embryo, Mammalian; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D020929:Mitogen-Activated Protein Kinase Kinases / Q000378:metabolism; D009474:Neurons / Q000187:drug effects* / Q000502:physiology; D009570:Nitriles / Q000494:pharmacology; D010446:Peptide Fragments / Q000494:pharmacology*; D028044:Phosphate-Binding Proteins; D011188:Potassium / Q000378:metabolism* / Q000494:pharmacology; D011494:Protein Kinases / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
D002070:Butadienes; C112303:CAVIN2 protein, human; D002352:Carrier Proteins; D004791:Enzyme Inhibitors; D009570:Nitriles; D010446:Peptide Fragments; D028044:Phosphate-Binding Proteins; C522412:TLQP-21 peptide; C113580:U 0126; D011494:Protein Kinases; D020929:Mitogen-Activated Protein Kinase Kinases; D011188:Potassium; D002118:Calcium